Bukwang Pharm Co Ltd

Bukwang Pharm maintains a strong liquidity position, with a current ratio of 2.57 and cash and equivalents amounting to KRW 96.2 billion. The company's debt-to-equity ratio is 0.24, indicating a conservative capital structure with limited leverage. The price-to-book ratio of 1.57 suggests that the market values the company at a moderate premium to its book value. Profitability metrics show a return on equity (ROE) of 3.69% and a return on assets (ROA) of 2.64%, both below the typical thresholds for high-performing pharmaceutical firms. The company's gross profit margin is 45.8%, calculated from a gross profit of KRW 91.9 billion on revenue of KRW 200.7 billion. However, operating income of KRW 11.2 billion and net income of KRW 12.6 billion indicate a stable but not exceptional performance in converting revenue to profit. Geographically, Bukwang Pharm's revenue is concentrated in South Korea, with no significant international operations disclosed. The company's business is primarily driven by domestic demand for prescription drugs, and there is no indication of diversified revenue streams across multiple regions. The company's growth trajectory appears modest, with no significant revenue growth or decline reported in the latest financial data. The company's capital expenditures were negative at KRW -11.2 billion, suggesting a reduction in investment in physical assets. Free cash flow is positive at KRW 1.8 billion, but the operating cash flow of KRW 21.5 billion indicates that the company generates sufficient cash to support its operations. Risk factors for Bukwang Pharm are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's shares outstanding remain unchanged between basic and diluted, indicating no near-term dilution risk. The conservative capital structure and strong liquidity position further support the low-risk profile. Recent filings and transcripts do not highlight any material events or strategic shifts for Bukwang Pharm. The company's operations and financial performance remain stable, with no significant changes in its business model or market position.